These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

619 related articles for article (PubMed ID: 33453391)

  • 1. Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase III trial
    Wu XH; Zhu JQ; Yin RT; Yang JX; Liu JH; Wang J; Wu LY; Liu ZL; Gao YN; Wang DB; Lou G; Yang HY; Zhou Q; Kong BH; Huang Y; Chen LP; Li GL; An RF; Wang K; Zhang Y; Yan XJ; Lu X; Lu WG; Hao M; Wang L; Cui H; Chen QH; Abulizi G; Huang XH; Tian XF; Wen H; Zhang C; Hou JM; Mirza MR
    Ann Oncol; 2021 Apr; 32(4):512-521. PubMed ID: 33453391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial.
    Li N; Zhu J; Yin R; Wang J; Pan L; Kong B; Zheng H; Liu J; Wu X; Wang L; Huang Y; Wang K; Zou D; Zhao H; Wang C; Lu W; Lin A; Lou G; Li G; Qu P; Yang H; Zhang Y; Cai H; Pan Y; Hao M; Liu Z; Cui H; Yang Y; Yao S; Zhen X; Hang W; Hou J; Wang J; Wu L
    JAMA Oncol; 2023 Sep; 9(9):1230-1237. PubMed ID: 37440217
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial.
    Mirza MR; Åvall Lundqvist E; Birrer MJ; dePont Christensen R; Nyvang GB; Malander S; Anttila M; Werner TL; Lund B; Lindahl G; Hietanen S; Peen U; Dimoula M; Roed H; Ør Knudsen A; Staff S; Krog Vistisen A; Bjørge L; Mäenpää JU;
    Lancet Oncol; 2019 Oct; 20(10):1409-1419. PubMed ID: 31474354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
    Mirza MR; Benigno B; Dørum A; Mahner S; Bessette P; Barceló IB; Berton-Rigaud D; Ledermann JA; Rimel BJ; Herrstedt J; Lau S; du Bois A; Herráez AC; Kalbacher E; Buscema J; Lorusso D; Vergote I; Levy T; Wang P; de Jong FA; Gupta D; Matulonis UA
    Gynecol Oncol; 2020 Nov; 159(2):442-448. PubMed ID: 32981695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of niraparib as maintenance treatment in older patients (≥ 70 years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.
    Fabbro M; Moore KN; Dørum A; Tinker AV; Mahner S; Bover I; Banerjee S; Tognon G; Goffin F; Shapira-Frommer R; Wenham RM; Hellman K; Provencher D; Harter P; Vázquez IP; Follana P; Pineda MJ; Mirza MR; Hazard SJ; Matulonis UA
    Gynecol Oncol; 2019 Mar; 152(3):560-567. PubMed ID: 30638768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
    González-Martín A; Pothuri B; Vergote I; DePont Christensen R; Graybill W; Mirza MR; McCormick C; Lorusso D; Hoskins P; Freyer G; Baumann K; Jardon K; Redondo A; Moore RG; Vulsteke C; O'Cearbhaill RE; Lund B; Backes F; Barretina-Ginesta P; Haggerty AF; Rubio-Pérez MJ; Shahin MS; Mangili G; Bradley WH; Bruchim I; Sun K; Malinowska IA; Li Y; Gupta D; Monk BJ;
    N Engl J Med; 2019 Dec; 381(25):2391-2402. PubMed ID: 31562799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy.
    Ison G; Howie LJ; Amiri-Kordestani L; Zhang L; Tang S; Sridhara R; Pierre V; Charlab R; Ramamoorthy A; Song P; Li F; Yu J; Manheng W; Palmby TR; Ghosh S; Horne HN; Lee EY; Philip R; Dave K; Chen XH; Kelly SL; Janoria KG; Banerjee A; Eradiri O; Dinin J; Goldberg KB; Pierce WF; Ibrahim A; Kluetz PG; Blumenthal GM; Beaver JA; Pazdur R
    Clin Cancer Res; 2018 Sep; 24(17):4066-4071. PubMed ID: 29650751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
    Mirza MR; Monk BJ; Herrstedt J; Oza AM; Mahner S; Redondo A; Fabbro M; Ledermann JA; Lorusso D; Vergote I; Ben-Baruch NE; Marth C; Mądry R; Christensen RD; Berek JS; Dørum A; Tinker AV; du Bois A; González-Martín A; Follana P; Benigno B; Rosenberg P; Gilbert L; Rimel BJ; Buscema J; Balser JP; Agarwal S; Matulonis UA;
    N Engl J Med; 2016 Dec; 375(22):2154-2164. PubMed ID: 27717299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
    Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
    Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Niraparib maintenance therapy using an individualised starting dose in patients with platinum-sensitive recurrent ovarian cancer (NORA): final overall survival analysis of a phase 3 randomised, placebo-controlled trial.
    Wu X; Zhu J; Yin R; Yang J; Liu J; Wang J; Wu L; Liu Z; Gao Y; Wang D; Lou G; Yang H; Zhou Q; Kong B; Huang Y; Chen L; Li G; An R; Wang K; Zhang Y; Yan X; Lu X; Lu W; Hao M; Wang L; Cui H; Chen Q; Abulizi G; Huang X; Tian X; Wen H; Huang Z; Dong J; Zhang C; Hou J; Mirza MR
    EClinicalMedicine; 2024 Jun; 72():102629. PubMed ID: 38745967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial.
    Del Campo JM; Matulonis UA; Malander S; Provencher D; Mahner S; Follana P; Waters J; Berek JS; Woie K; Oza AM; Canzler U; Gil-Martin M; Lesoin A; Monk BJ; Lund B; Gilbert L; Wenham RM; Benigno B; Arora S; Hazard SJ; Mirza MR
    J Clin Oncol; 2019 Nov; 37(32):2968-2973. PubMed ID: 31173551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Coleman RL; Oza AM; Lorusso D; Aghajanian C; Oaknin A; Dean A; Colombo N; Weberpals JI; Clamp A; Scambia G; Leary A; Holloway RW; Gancedo MA; Fong PC; Goh JC; O'Malley DM; Armstrong DK; Garcia-Donas J; Swisher EM; Floquet A; Konecny GE; McNeish IA; Scott CL; Cameron T; Maloney L; Isaacson J; Goble S; Grace C; Harding TC; Raponi M; Sun J; Lin KK; Giordano H; Ledermann JA;
    Lancet; 2017 Oct; 390(10106):1949-1961. PubMed ID: 28916367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.
    Oza AM; Matulonis UA; Malander S; Hudgens S; Sehouli J; Del Campo JM; Berton-Rigaud D; Banerjee S; Scambia G; Berek JS; Lund B; Tinker AV; Hilpert F; Vázquez IP; D'Hondt V; Benigno B; Provencher D; Buscema J; Agarwal S; Mirza MR
    Lancet Oncol; 2018 Aug; 19(8):1117-1125. PubMed ID: 30026000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world safety and effectiveness of maintenance niraparib for platinum-sensitive recurrent ovarian cancer: A GEICO retrospective observational study within the Spanish expanded-access programme.
    Cueva JF; Palacio I; Churruca C; Herrero A; Pardo B; Constenla M; Santaballa A; Manso L; Estévez P; Maximiano C; Legerén M; Marquina G; de Juan A; Quindós M; Sánchez L; Barquin A; Fernández I; Martín C; Juárez A; Martín T; García Y; Yubero A; Gallego A; Martínez Bueno A; Guerra E; González-Martín A
    Eur J Cancer; 2023 Mar; 182():3-14. PubMed ID: 36706655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study.
    Ai X; Pan Y; Shi J; Yang N; Liu C; Zhou J; Zhang X; Dong X; He J; Li X; Chen G; Li X; Zhang H; Liao W; Zhang Y; Ma Z; Jiang L; Cui J; Hu C; Wang W; Huang C; Zhao J; Ding C; Hu X; Wang K; Gao B; Song Y; Liu X; Xiong J; Liu A; Li J; Liu Z; Li Y; Wang M; Zhang B; Zhang D; Lu S
    J Thorac Oncol; 2021 Aug; 16(8):1403-1414. PubMed ID: 33915252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial.
    Gonzalez Martin A; Sanchez Lorenzo L; Colombo N; dePont Christensen R; Heitz F; Meirovitz M; Selle F; van Gorp T; Alvarez N; Sanchez J; Marqués C
    Int J Gynecol Cancer; 2021 Apr; 31(4):617-622. PubMed ID: 33318079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial.
    Li N; Zhang Y; Wang J; Zhu J; Wang L; Wu X; Yao D; Wu Q; Liu J; Tang J; Yin R; Lou G; An R; Zhang G; Xia X; Li Q; Zhu Y; Zheng H; Yang X; Hu Y; Zhang X; Hao M; Huang Y; Lin Z; Wang D; Guo X; Yao S; Wan X; Zhou H; Yao L; Yang X; Cui H; Meng Y; Zhang S; Qu J; Zhang B; Zou J; Wu L
    J Clin Oncol; 2022 Aug; 40(22):2436-2446. PubMed ID: 35404684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
    Ledermann J; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott CL; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Dougherty B; Orr M; Hodgson D; Barrett JC; Matulonis U
    Lancet Oncol; 2014 Jul; 15(8):852-61. PubMed ID: 24882434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
    Ledermann JA; Oza AM; Lorusso D; Aghajanian C; Oaknin A; Dean A; Colombo N; Weberpals JI; Clamp AR; Scambia G; Leary A; Holloway RW; Gancedo MA; Fong PC; Goh JC; O'Malley DM; Armstrong DK; Banerjee S; García-Donas J; Swisher EM; Cameron T; Maloney L; Goble S; Coleman RL
    Lancet Oncol; 2020 May; 21(5):710-722. PubMed ID: 32359490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial.
    Belotte J; Felicetti B; Baines AJ; YoussefAgha A; Rojas-Espaillat L; Ortiz AG; Provencher D; Vázquez RM; Cortijo LG; Zeng X
    Trials; 2024 May; 25(1):301. PubMed ID: 38702828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.